Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
In conclusion we report that the
2022-12-02

In conclusion, we report that the widely prescribed drug VPA exerts therapeutic effects on optic nerve demyelination and retinal degeneration in a mouse model of MS. Our findings raise an interesting possibility that combination therapy of VPA and ASK1 inhibition may be useful for treatment of autoi
-
No starting dose adjustment is needed for mild or moderate
2022-12-02

No starting dose adjustment is needed for mild or moderate renal impairment and mild hepatic impairment (Child-Pugh A classification) though use in patients with severe hepatic impairment (Child-Pugh classification Class C, 10–15 points score) is not recommended.8, 9, 10, 13 Drug interaction & ad
-
br Funding This study was supported by a grant
2022-12-02

Funding This study was supported by a grant from the Science and Technology Program of Guangzhou (No. 2014Y2-00181) and the personnel training program of Southern Medical University (No. PY2015N023). Conflict of interest statement Authors’contributions Introduction Chronic cerebral hypo
-
Not all secondary metabolites or natural products
2022-12-02

Not all secondary metabolites or natural products can be fully synthesized due to their very complex structures that are too difficult and expensive on industrial scale. Hence, there is an urgent need to search for alternative remedies as naturally occurring biologically active secondary metabolites
-
In this study we designed and synthesized two ALK PROTACs
2022-12-01

In this study, we designed and synthesized two ALK PROTACs (degraders), 5 (MS4077) and 6 (MS4078), by linking ceritinib and pomalidomide [45] through two different linkers. Using human ALCL and NSCLC cells, we characterized both compounds in a battery of assays to demonstrate their effects on reduci
-
br Methods br Results and discussion
2022-12-01

Methods Results and discussion Conclusions Acknowledgements The authors thank Dr. Francois Alhenc-Gelas (then INSERM U367, Paris, France), who kindly provided the plasmid for truncated soluble recombinant human ACE – WTΔ, Dr. Elena Arablinskaya (Institute of Phtiziopulmonology, Moscow, R
-
The present study has several limitations
2022-12-01

The present study has several limitations. First, the results were obtained using RAW264.7 cells, which are derived from BALB/c mice infected with the Abelson leukemia virus (Raschke et al., 1978). However, these cells, which are a commonly used mouse macrophage cell line, show properties similar to
-
The diagnosis of ICP is
2022-12-01

The diagnosis of ICP is currently based on the presence of pruritus, raised fasting serum TBS levels above 10μmol/L, and/or elevated serum transaminases (in the absence of diseases that cause cholestasis or pruritus) as well as spontaneous relief of signs and symptoms within four to six weeks after
-
While the yeasts and see Glossary each contain
2022-12-01

While the yeasts and (see Glossary) each contain only one Aurora homolog, Ipl1p (increase in ploidy 1) and Ark1 (Aurora-related kinase 1), respectively 5, 6, , and Xenopus laevis contain two Aurora kinases: Aurora A and Aurora B [4]. Mammals have three Aurora kinases, A, B, and C (Figure 1). In anim
-
Demonstration of in vivo efficacy of potential
2022-12-01

Demonstration of in vivo efficacy of potential chemopreventive agents in animal models is necessary for their clinical development. Our present study provides experimental evidence that CuB 0.1μmol by oral administration (for 2weeks before the cancer cell injection, 5days per week) significantly inh
-
The phylogenetic relationship demonstrates that both bovine
2022-12-01

The phylogenetic relationship demonstrates that both bovine and porcine 12/15-LO is more related to the human enzyme than the rabbit enzyme, despite the fact that the rabbit reticulocyte enzyme is a 15-lipoxygenase. The rabbit is one single species that expresses a 12/15 LO with 15-LO activity while
-
A high throughput screening campaign
2022-12-01

A high-throughput screening campaign led to the discovery of the first series of both potent and selective ATR kinase inhibitors by Vertex Pharmaceuticals (Charrier et al., 2011). One of these compounds, VE-821, was shown to be a potent ATP-competitive inhibitor of ATR with minimal cross-reactivity
-
Regulators of the DDR have therefore become attractive targe
2022-12-01

Regulators of the DDR have therefore become attractive targets for cancer therapy primarily through two potential approaches. First, to be used as chemo- or radiosensitisers to increase the effectiveness of standard genotoxic treatments and to help prevent or overcome the development of resistance.
-
In our study caspase and DRAM were identified
2022-12-01

In our study, caspase3 and DRAM were identified as being involved in full-length AIFM1-induced apoptosis. Caspase3 is best known for its role in the execution phase of apoptosis in both intrinsic and extrinsic apoptotic pathways [17]. The members of the caspase family are generally in inactive pro-f
-
The objectives of this study were to investigate the
2022-12-01

The objectives of this study were to investigate 1) the mRNA and protein expression of apelin and APJ in porcine ovarian follicles of different sizes, and their immunolocalization and concentrations in follicular fluid and ovarian follicle, and 2) the direct effect of recombinant human apelin-13 on
14395 records 351/960 page Previous Next First page 上5页 351352353354355 下5页 Last page